Schwartz DH - Search Results

1

Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5.

John R, Arango-Jaramillo S, Finny GJ, Schwartz DH. John R, et al. Among authors: schwartz dh. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):1-8. doi: 10.1097/00126334-200401010-00001. J Acquir Immune Defic Syndr. 2004. PMID: 14707786

2

Rapid communication: development of in vitro resistance to macrophage-tropic- and T-cell-line-adapted HIV-1 strains among HIV-positive volunteers treated with highly active antiretroviral therapy.

Castillo RC, Arango-Jaramillo S, John R, Turner BC, Zimmerman E, Schwartz DH. Castillo RC, et al. Among authors: schwartz dh. J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):197-202. doi: 10.1097/00126334-200007010-00001. J Acquir Immune Defic Syndr. 2000. PMID: 10969342

3

Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons.

Schwartz DH, Castillo RC, Arango-Jaramillo S, Sharma UK, Song HF, Sridharan G. Schwartz DH, et al. J Infect Dis. 1997 Nov;176(5):1168-74. doi: 10.1086/514109. J Infect Dis. 1997. PMID: 9359715

4

Modeling partially effective HIV vaccines in vitro.

John R, Arango-Jaramillo S, Self S, Schwartz DH. John R, et al. Among authors: schwartz dh. J Infect Dis. 2004 Feb 15;189(4):616-23. doi: 10.1086/381393. Epub 2004 Feb 4. J Infect Dis. 2004. PMID: 14767814

5

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.

Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, Schwartz DH. Castillo RC, et al. Among authors: schwartz dh. J Infect Dis. 2000 Mar;181(3):897-903. doi: 10.1086/315300. J Infect Dis. 2000. PMID: 10720510

6

Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.

Schwartz DH, Laeyendecker OB, Arango-Jaramillo S, Castillo RC, Reynolds MJ. Schwartz DH, et al. Lancet. 1997 Jul 26;350(9073):256-9. doi: 10.1016/S0140-6736(97)01500-6. Lancet. 1997. PMID: 9242803 Free article.

7

A novel factor produced by placental cells with activity against HIV-1.

Sharma UK, Trujillo J, Song HF, Saitta FP, Laeyendecker OB, Castillo R, Arango-Jaramillo S, Sridharan G, Dettenhofer M, Blakemore K, Yu XF, Schwartz DH. Sharma UK, et al. Among authors: schwartz dh. J Immunol. 1998 Dec 1;161(11):6406-12. J Immunol. 1998. PMID: 9834132

8

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.

Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. Clark AG, et al. Among authors: schwartz dh. J Acquir Immune Defic Syndr (1988). 1992;5(1):52-9. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1738087

9

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.

Perales MA, Schwartz DH, Fabry JA, Lieberman J. Perales MA, et al. Among authors: schwartz dh. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7648281 Clinical Trial.

10

Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein.

Schwartz DH, Cosentino LM, Shirai A, Conover J, Daniel S, Klinman DM. Schwartz DH, et al. J Acquir Immune Defic Syndr (1988). 1994 May;7(5):447-53. J Acquir Immune Defic Syndr (1988). 1994. PMID: 8158537 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters